id: NEW:mesenchymal_stem_cell_therapy_to_NEW:hba1c_level
name: Mesenchymal Stem Cell Therapy â†’ Hemoglobin A1c Level
from_node:
  node_id: NEW:mesenchymal_stem_cell_therapy
  node_name: Mesenchymal Stem Cell Therapy
to_node:
  node_id: NEW:hba1c_level
  node_name: Hemoglobin A1c Level
direction: negative
category: biological
mechanism_pathway:
- 'Step 1: Mesenchymal stem cells (MSCs) are administered to patients with diabetes
  mellitus'
- 'Step 2: MSCs exhibit immunomodulatory properties that reduce inflammation and autoimmune
  attack on pancreatic beta cells'
- 'Step 3: MSCs may promote regeneration or preservation of functional beta cell mass
  through paracrine signaling'
- 'Step 4: Improved beta cell function leads to better insulin secretion and glucose
  regulation'
- 'Step 5: Enhanced glycemic control over time results in decreased glycation of hemoglobin,
  reducing HbA1c levels'
evidence:
  quality_rating: A
  n_studies: 7
  primary_citation: 'Jingjing He et al. 2021. Clinical efficacy on glycemic control
    and safety of mesenchymal stem cells in patients with diabetes mellitus: Systematic
    review and meta-analysis of RCT data. PLoS ONE.'
  supporting_citations: []
description: 'Meta-analysis of 7 randomized controlled trials (413 participants) demonstrates
  that mesenchymal stem cell therapy significantly reduces HbA1c levels in patients
  with diabetes mellitus. The MSC treatment group showed a mean difference of -1.32%
  (95% CI: -2.06 to -0.57) in HbA1c reduction from baseline, and -0.87% (95% CI: -1.53
  to -0.22) compared to control groups. The therapy appears safe with no significant
  difference in adverse events between treatment and control groups, though hypoglycemia
  was the most common adverse reaction (29.95%).'
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: -0.87
    type: mean_difference
    ci_lower: -1.53
    ci_upper: -0.22
  p_value: 0.01
  sample_size: 413
moderators:
- name: Diabetes type
  direction: strengthens
  strength: moderate
  description: The meta-analysis included both type 1 and type 2 diabetes patients,
    with potential differential effects based on diabetes etiology
- name: Follow-up duration
  direction: strengthens
  strength: moderate
  description: Longer follow-up periods may show sustained or enhanced HbA1c reduction
    effects
